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Abstract  
Acute coronary syndrome (ACS) consists of unstable angina pectoris, non-ST segment elevation myocardial 
infarct ion and ST segment elevate ion myocardial infarction.  The aim of the study was to compare the vibration  
some hormones levels in the Acute coronary syndrome patients and control groups and This study aimed to 
investigate the association between two single nucleotide polymorphisms (−1562C>T, of the MMP-9 gene in 
patients with ACS in the Iraq population. 
Subjects and methods: This study was conducted between / mrjan teaching hospital in Babylon Province 
between November 2012- Aprial 2013and it was carried out at the coronary care unit  / in Babylon province/Iraq .  
This patient-control study was composed of 60 ACS patients with age 53.38 ± 9.51 and 30control withe age  
51.43 ± 7.81subjects, The present study is divided into two main parts: physio-biochemical and molecular parts. 
The physiological part involved hormonal assay( troponin and endothelin-1) while molecular part included The 
genotypes of the  selected SNPs were determined by the method of polymerase chain reaction and restriction 
fragment length polymorphism (RFLP-PCR). The relationship between the polymorphism of the MMP-9 gene 
and the severity of Acute coronary syndrome with negative medical history. 
The result of this study showed that patients with Acute coronary syndrome both males and females had 
significantly troponin and elevated Endothelin -1 in patient than control<0.001**(**p value ≤ 0.01 was 
significant).Analysis of the SNPs showed that the frequency of CT and TT genotypes in patients with ACS was 
significantly higher than that in the control group (ACS vs. controls; CT+TT: (85%Vs 36%). 
Keywords:single nucleotide polymorphisms, troponin, endotheline, MMP-9  
 
Introduction  
 ACS is mainly caused by coronaryatherosclerotic plaque rupture or erosion and subsequentintracoronary 
thrombus formation (Davies MJ,1996). Age, gender,smoking, hypertension, hypercholesterolemia, 
diabetesmellitus, obesity and sedentary lifestyle are reported tobe associated with ACS but the exact 
mechanismof ACS is still not clear ( Anderson et al.,1991). Acute coronary syndrome (ACS) consists of 
unstableangina pectoris, non-ST segment elevation myocardialinfarct ion and ST segment elevat ion 
myocardialinfarction. The pathogenic mechanism of ACS ismost often based on thrombosis secondary to 
plaquerupture in atherosclerosis (ASC) (Liu et al.,2006).Vascular diseases, including coronary artery disease, are 
the leading cause of death in developed countries. The data indicate that persons under 45 years of age constitute 
approximately 10% of all patients with myocardial infarction (Doughty et al., 2002). Among young people, the 
leading factor for myocardial infarction (besides the classic risk factors of hypercholesterolemia, arterial 
hypertension, smoking, and diabetes mellitus) is a positive family history among first-degree relatives 
(Garoufaliset al., 1998) (Sakowiczet al., 2010b), perhaps because environmental factors have had less time to 
exert a dominating influence on the disease process in young people (Chaeret al., 2004). 
Approximately 90% of all cases of myocardial infarction are the result of acute thrombus, causing obstruction of 
an artery vessel in places of atherosclerosis plaque rupture (Sakowiczet al. 2010b). The etiopathogenesis of 
atherosclerosis plaque is still not clear. Several theories or hypotheses about atherogenesis have been proposed. 
The most probable is the unified theory in which atherosclerosis is caused by complicated interactions among 
cells of the endothelium, blood cells, and lipoprotein. Damage to the endothelium leads to its dysfunction and 
activation (Libby 2002). This activation is related to the increased expression of chemoattractant cytokines, 
lecithin-like oxidized low-density lipoprotein receptor-1 (LOX-1), and adhesion molecules such as selectin E, 
intracellular adhesion molecule type 1 (ICAM1), vascular adhesion molecule (VCAM), and platelet endothelial 
cell adhesion molecule type 1 (PECAM1) (Libby 2002). There is a genetic associationbetween polymorphic 
variants in candidate genes andatherosclerosis. 
The matrix metalloproteinase (MMP)family is one of the potential candidate gene 
systems.matrixmettalopritenase(MMP) family are involved in the breakdown of the extracellular matrix in 
normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as 
in disease processes, such as arthritis and metastasis (Visse and Nagase ,2003). mmp_9 play significant role in 
the progression of atherisclerrosis ,plaque rupture and ischemic heart disease (Visse and Nagase ,2003). Most 
MMPs are secreted as inactive proproteins which are activated when cleaved by extracellular 
proteinases.(Henneyet al 200) reported that genetic change which affects the expression of MMPs may 
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contribute to the occurrence of cardiovascular disease. Matrix metallopeptidase 9 (MMP-9), also known as 92 
kDa type IV collagenase, 92 kDagelatinase or gelatinase B (GELB), is an enzyme that in humans is encoded by 
the MMP9 gene. MMP-9 is highly expressed in the vulnerable regions of atherosclerotic plaques. For this reason, 
MMP-9 plays a key role in vascular remodeling and development of atherosclerotic lesion, and plays a potential 
role in arterial plaque rupture (Galis and Khatri ,2002). The rol of MMP_9 gene are relatedto presence and 
severity of CAD (Morgan el at 3003). ( Zhanget al.,1999) have identified several single nucleotide 
polymorphisims in the mmp_9 gene including the C . the 1562T allele has a higher promoter activity than the C 
allal and may influence the severity and extent of coronary artery stenosis (Morgan et al., 2003). 
 ET-1 is a 21-amino acid peptide and represents the major isoform of the endothelin peptide family (Khan 
IA.,2005) which also includes ET-2, ET-3 and ET-4. The endothelin peptides are produced by endothelial and 
smooth muscle cells, neural, renal, pulmonary and inflammatory cells. ET-1 is the most potent vasoconstrictor 
known. The inactive precursor is converted into its active form by ET converting enzyme. ET-1 acts through two 
receptors, ET-A and ET-B. ET-A receptors lead to increased intracellular calcium concentrations and induce 
vasoconstriction and cell proliferation. ETB receptors mediate the release of nitric oxide and prostacyclin and 
therefore cause vasodilatation. They are also involved in the clearance of ET-1 and inhibit the action of ET 
converting enzyme (Spiekeret al.,2001) ET-1 has also been found to play an important role in the pathogenesis 
of hypertension, congestive heart failure and regulation of renal function(Spiekeret al.,2001). 
ET-1 levels are positively correlated with the extent of atherosclerosis. Other studies have shown that in patients 
with coronary artery disease tissue ET-1 levels are related to the extent of angina( Berger and Pacher .,2003) . 
ET-1 promotes direct vasoconstriction, induces smooth muscle cell proliferation, stimulates adhesion of 
neutrophils to the endothelium and platelet aggregation. (Knofleret al.,1995) It also antagonises the action of 
nitric oxide. 
Cardiac troponin is composed of three subunits T, I, and C, which are the products of different genes. The total 
mass of the troponin complex is minuscule when compared with the protein mass of other myofibrillar proteins 
like actin and myosin. However, both pattern of cardiac troponin (cTn) T when compared with the monophasic 
pattern seen with cTnI (Thygesenet al .,2010). The release pattern of cTnT is different in non-reperfused MI and 
may vary with small MIs. Although the exact reason for this different release kinetics is still illusive, cTnT 
differs from cTnI with respect to higher molecular weight, higher fraction of unbound cTnT, less degradation, 
whereas cTnI is more frequently found as binary or tertiary complex in blood. The diagnosis of MI has thus 
evolved following the introduction of routine troponin testing, resulting in the redefinition of MI by the joint 
European Society of Cardiology (ESC)/American College of Cardiology (ACC) in 2000 (Alpert et al.,2000) . 
Based on this consensus document, any amount of myocardial damage, as detected by serum troponin and 
associated with evidence of ischemia, should be considered an MI. It is increasingly recognized that elevated 
troponin levels occur in many patients who do not have evidence of flow-limiting coronary artery disease 
( Ammannet al., 2009). In addition to nonthrombotic cardiac conditions (myocardial contusion, infiltrative 
myocardial diseases), nonthromboticnoncardiac diagnoses (sepsis, pulmonary embolism, stroke, renal failure) 
are also associated with elevated levels of troponin. Given this observation, it is generally considered 
inappropriate to use elevated troponin levels as the only diagnostic criterion for MI ( Luepkeret al .,2003). 
 
Subjects and Methods 
Study Design, Setting and Data Collection Time 
 Case-control study was conducted between November 2012- Aprial 2013and it was carried out at the coronary 
care unit / in Babylon province/Iraq .  
Study Population 
 The study subjects comprised from 60 patients suffer frome ACS randomly selected fromemrjan teaching 
hospital (50 male and 10 female) as ACS patients group with age average (3o-65 year), the control group study 
included 30 people apparently healthy that included 20 male and 10 female with age average (33-65 year) ,this 
control group matched with patient group. All subjects in this study were taken written consent 
beforparticipatian in this study. 
Exclusion Criteria 
The excluded include patients DM, hypertension ,hepatitis , heart failure, renal failure, liver disease, malignant 
disease ,patients on chemotherapy , etc. and excluded patients who suffer from complication MI. Questionnaire 
taken from the patient included : age, sex ,occupation ,types of MI , smoking habit, alcohol intake, pervious 
attack, blood pressure, , and family history of MI,past medical history 
DNA extraction 
DNA was extracted from freezing blood according to kit leaflet (genaid, genomic DNA extraction kit). 
PCR of MMP-9 ** 
 Amplification of gene by PCR performed according to table A using sequence of primers in table B  
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Table (A)  program was used for amplification the target DNA fragments(for MMP-9 gen) 
Cycles Function Time(min) Temperature(
O
C) Stage 
 Initial denaturation 0.30 94 1 
 DNA denaturation 0.30 94 2 
30 Primer annealing  1 67 
 Template elongation 1 72 
 Final elongation 5 72 3 
Hold Incubation - 4 4 
 
Table (B) sequence of MMP-9 ** primers 
Sequences Primer gen name 
F:5'-GCC TGG CAC ATA GTA GGC CC-3' 
 
 
MMP-9 ** 
R:5'-CTT CCT AGC CAG CCG GCA TC-3' 
 
RFLP-PCR 
1- Prepare the Sph I enzyme and dilute the buffer enzyme  10X to 1X. 
2- taked  100 µl from buffer enzyme (10X) and add  900 µl d.d.w in  Eppindorf tube  to prodused buffer 1X . 
3- 8 µl of amplified product  (422 pb fragment) with 2.5 µl from enzyme and add 39.5 µl with buffer  enzyme 
(1x). 
4- put the mixture Eppindorf  tubes and incubated at 37 C
ᵒ
 for 1-2 hour by using thermocycler (Cleaver 
Scientific). 
5- Digested amplified DNA fragments were electrophoresed on 1% agaros, ,(1X) TBE buffer (40 min at 75 V) 
and the bands visualized after staining with ethidium bromide under UV light. A 100 base-pair ladder were used 
as a size marker for estimation of fragment sizes. 
Blood collection  
About five milliliters of venous blood were collected from each subject in the study. blood  were separated by 
centrifugation at 3000 rpm for 15 min for separated serawhich remaining stored frozen at -20 ºC until hormonal 
assayed. Troponin Kit Biomerieux (France) msurmeant by Vides and endothelin Kit enzolifesincese(USA) 
msurmeant by Eliza reader & washerBiotek – USA. 
Results  
Table1 shows the association of study groups (Cases Vs controls) by sex , residence, occupation, family history , 
smoking habit, alcohol intake , history of previous attacks and blood pressure level . There was significant 
association between development of myocardial infarction and occupation, presence of smoking habit , presence 
of history of previous attacks and blood pressure level , meanwhile there was no significant association between 
development of myocardial infarction and sex , residence , family history and alcohol intake. Majority of patients 
with MI were male (83.3%) , (70%) were not employed and (78.3%) came from urban area . 
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Table (1) The association of study groups by study variables 
* Normal blood pressure (<120 and <80) , pre-hypertension (120-139 or 80-89) and hypertensive (≥140 or ≥90). 
 
Table 2 show the mean differences of age, heart rate and BMI for both gender of myocardial infarction and 
control subjects . There were significant mean differences of heart rate and body mass index between myocardial 
patients and control subjects ,meanwhile there were no significant mean differences of age between case and 
control groups and no significant mean differences of age ,heart rate and BMI for both male and female gender . 
 
Table (2) Mean differences of age, heart rate and BMI for both gender of myocardial infarction and 
control subjects 
P value 
of 
group 
P value 
of 
gender 
Control 
(Mean ± SD) 
Case 
(Mean ± SD) 
Group 
 
 
Indices Female Male Female Male 
0.335 0.09 48.85 ± 6.46 52.21 ± 8.15 61.00 ± 6.42 51.86 ± 9.33 Age ( years) 
0.009** 0.562 74.14 ± 1.21 75.65  ± 1.64 84.30 ± 16.58 79.46 ± 13.67 
Heart rate 
(beat/minute) 
<0.001** 0.891 29.28 ± 4.76 29.84 ± 4.15 25.98 ± 3.40 25.97 ± 3.32 BMI (Kg/M
2
) 
Table 3 shows the association of study groups (Cases Vs controls) by physiological markers of heart disease 
(endothelin , troponin) . There was significant association between development of myocardial infarction and 
increment of these markers . 
  
Variable Case Control χ
2
 df P-value 
Odds 
ratio 
95% CI 
Sex 
Male 50(83.3%) 23(77%)  
0.58 
 
1 
 
0.446 
 
1.52 
 
0.514-4.503 Female 10 (16.7%) 7(23%) 
residence 
Rural 13 (21.7%) 3 (10%)  
1.86 
 
1 
 
0.172 
 
2.48 
 
0.651-9.523 Urban 47 (78.3%) 27(90%) 
Occupation 
Not employed 42 (70%) 5(17%)  
22.8 
 
1 
 
<0.001** 
 
11.66 
 
3.85-35.317 Empolyee 18 (30%) 25(83%) 
family history 
Present 22 (37%) 13(43%)  
0.37 
 
1 
 
0.541 
 
0.75 
 
0.31-1.849 Absent 38 (63%) 17(57%) 
Smoking habit 
Present 33 (55%) 6(20%)  
9.97 
 
1 
 
0.002** 
 
4.88 
 
1.747-13.651 Absent 27 (45%) 24(80%) 
History of previous attacks 
Present 14 (23%) 1(3%)  
5.76 
 
1 
 
0.016* 
 
8.82 
 
1.1-70.7 Absent 46 (77%) 29(97%) 
Alcohol intake 
Present 2 (3%) 0 (0%)   
0.551
a 
  
Absent 58 (97%) 30(100%) 
Blood pressure       
Normal 23 (38%) 2 (7%) 
18.99 2 <0.001** Pre-hypertensive 21 (35%) 25 (83%) 
Hypertensive 16 (27%) 3 (10%) 
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Table (3) The association of study groups (Cases Vs controls) by physiological markers
Variable Case
Endothelin  
Normal value (1.2-2.5 
pg/ml) 
3 (5%) 
High (>2.5 pg/ml)               45 (75%)         1 (3%)
Low (<1.2 pg/ml) 12 (20%)
Troponin 
High (0.01) and above 50(83%)
Normal value 
 (< 0.01) 
10(17%)
 
Figure 1 shows the distribution of the cases by types of myocardial infarction .Majority (42%).
of the cases presented with inferior MI
Figure(1) Distribution of cases by types of MI
 
Figure 2 shows the distribution of the study population by Body mass index . Majority (48%) of the cases were 
pre-obese while majority (47%)  of control were obese .
Figure (2) Distribution of study population by BMI
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figure ( 3) Electrophorese  patteren of  DNA extraction from blood for patient ACS and control % agarose 75V, 
20 AM, for 1h (10 µl in each well). 
 
 
figure ( 4) Electrophorese  patteren of  PCR product for MMP-9 gene , this amplification  prduse one band 435 
bp both patient and and control 1% agarose 75V, 20 AM, for 1h (10 µl in each well). 
 
figure ( 5) Electrophorese patteren of RFLP- PCR product for 435 bp both with restriction enzyme Spha I, 1% 
agarose 75V, 20 AM, for 120 m (10 µl in each well). 
Lane 1:- DNA lader 100 bp 
Lane,3,5,10,12:-showing wild type (CC) genotype. 
Lane 6:- showing mutant homozygote (TT) genotype. 
Lane 2,4,8,9,11,12:- showing mutant homozygote(CT) genotype. 
 
Discussion 
       The diagnosis of acute myocardial infarction (AMI) has traditionally been based on the characteristic 
clinical history, electrocardiographic abnormalities and increased serum concentrations of cardiac marker 
enzymes. As the differential diagnostic value of chest pain is limited and the electrocardiographic changes have 
various degrees of sensitivity and specificity (Rude et al., 1983), 
The results of the present study show that the patients with  ACS of ECG is higher type MI inferior 42% other 
than type MI as show in the( figure 1),ECG diagnosis of myocardial infarction may not be evident during initials 
hours at all the times and it is always essential to diagnose myocardial infarction earlier for timely therapeutic 
intervention.  Because cardiac troponin is a sensitive and specific measure of myocardial necrosis, it is the 
preferred biomarker for use in the diagnosis of acute MI. Although an elevated troponin indicates myocardial 
necrosis so in the present study show that the patients with ACS whether male or female, had significantly 
higher  troponin concentration than control group as show (table 3). 
According to Katuset al (1993) Troponin T is elevated more than twice the analytical sensitivity of the assay (0.5 
ng/ml) in all patients with infarction Troponin T appeared in the serum as early as 3 hours after the onset of chest 
pain in 50% of patients and remained elevated in all patients for more than 130 hours. Thus cardiac Troponin T 
measurement is particularly useful in clinical ircumstances in which traditional enzyme determiations fail to 
diagnose myocardial cell damage efficiently(Gerhardt et al.,1992). 
The incidence and prevalence rates of elevated levels of troponincited in the literature vary widely, ranging from 
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15% to 70% of patients (Noble et al.,1999) Recent studies have examined thefrequency of elevated troponin 
levels excluding those patients with underlying coronary heart disease (Ammannet al.,2003). 
The results of the present study show that the patients ACS ,whether male or female, had elevated endothlin-1 
concentration than control group and higher significantly between them as show( table 3). 
Experimental studies have shown that endothelin may be produced by activated human macrophages 
(Ehrenreichet al .,1990) and has been also implicated in cytokine(Ruettenet  al.,1997) and vascular cell adhesion 
molecule expression(Ishizuka et al .,1999). 
studies have suggested that plasma endothelin is increased in patients with acute coronary 
syndromes(Wieczoreket al .,1994). ET antagonists have an adverse effect on myocardial contractility in healthy 
individuals with normal ET-1 plasma levels but improve contractility in patients with advanced ventricular 
dysfunction(Khan ,2005). 
    ET-1 levels are positively correlated with the extent of atherosclerosis. Other studies have shown that in 
patients with coronary artery disease tissue ET-1 levels are related to the extent of angina( Berger and 
Pacher .,2003) . The effects of ET-1 on the heart are multiple(Khan IA.,2005) Normal ET-1 plasma levels 
produce a positive inotropic effect through an increase in intracellular calcium, whereas elevated plasma levels 
of ET-1 result in a decline in cardiac output. This is because ET- 1 has a predominantly vasoconstrictive effect, 
at both peripheral and coronary level, thus resulting in increased afterload and reduced myocardial perfusion. ET 
antagonists have an adverse effect on myocardial contractility in healthy individuals with normal ET-1 plasma 
levels but improve contractility in patients with advanced ventricular dysfunction(Khan ,2005). 
This is the first study on the two potentially functional polymorphisms of the MMP-9 gene in relation to 
ACS(MI) susceptibility in the Iraq population. The data of this study demonstrated that the −1562 T allele of the 
MMP-9 gene is significantly associated with an increased risk of ACS. The frequencies of C/C,C/T and T/T 
ofMMP-9 (−1562C>T) polymorphism were 27(45%),24(40%),9(15%) in the ACS group, and 
19(63.3%),8(26.7%),3(10%)  in the control group The homozygote TT and the heterozygote CT were more 
frequent in the ACS than in the control group(85%) Vs(36%). 
   MMP-9 possesses proteolytic activity on type IV collagen, a major constitute of the basement membrane that 
surrounds every vascular smooth muscle cell and underlies the endothelium in the blood vessel wall( Newby AC 
2005). 
The human MMP-9 gene is located on chromosome b20q12.2-13.1, (Zhang et al.,1999)found a number of single 
nucleotide polymorphisms (SNPs) in the promoter, coding and untranslated regions. Of these, two 
polymorphisms, namely promoter −1562C>T polymorphism and codon 279 polymorphism (R279Q), are of 
special significance. Functional studies indicate that the −1562C>T polymorphism has an al lelespecific effect 
on MMP-9 transcription. DNA-protein interaction assays have revealed that the sequence between nucleotide 
position −1567 and −1559 relative to the transcription start site of the MMP9 gene, which encompasses the 
−1562 polymorphic site, can interact with a nuclear protein, but its mechanism is still unknown(Zhang et 
al.,1999). 
Functional studies indicate that the −1562C>T polymorphism has an allele-specific effect on MMP- 9 
transcription. In this study we found that −1562CT/ TT genotypes were associated with a significantly increased 
risk of ACS. A genetic epidemiological study( Morgan et al.,2003) indicated that T-1562 allele carriers are 
predisposed to the development of coronary atherosclerosis, which causes coronary stenosis. (Zhang et al.,1999). 
reported a functional 1562C>T polymorphism in the promoter region of MMP- 9. Transfection experiments and 
DNA-protein interaction assays indicated that the T allele had a higher activity. In addition,(Blankenberget 
al.,2003) reported that plasma MMP- 9 levels were also higher in −1562T allele carriers than in non-carriers. A 
study( Medley et al., 2004) on aortic tissues showed that MMP-9 mRNA levels, MMP-9 protein levels and 
MMP- 9 activity were higher in −1562 T allele carriers than in non-carriers. MMP-9 knockout studies (Galiset 
al., 2002; Johnson and Galis ,2004)in mice also demonstrated a role of MMP-9 in the development of 
atherosclerosis. Compared with MMP-9 wild-type mice, MMP-9 deficient mice had fewer and smaller 
atherosclerotic lesions (Johnson and Galis ,2004) . 
Thus, increased vascular smooth muscle migration and macrophage infiltration are likely to explain increased 
coronary atherosclerosis in carriers of the MMP-9 high expression −1562T allele in humans. These findings 
suggest that the −1562 C>T polymorphism not only affect the MMP-9 promoter activity in vitro experiments, 
but also influence the MMP-9 transcription in vivo, and this effect is translated into differences in MMP-9 
protein level and activity between individuals with different MMP-9 genotypes. 
Our study result showed that serum MMP-9 level was significantly increased in STEMI, indicated greater 
damage or degradation of extracellular matrix from plaque rupture. MMP-9 contributes to the vulnerability of 
coronary atherosclerotic plaques which tends to rupture or erode and precipitates acute coronary events(Galis 
and Khatri ,2002) . (Fiotti et al.,2006) reported that the MMP-9 promoter microsatellite polymorphism 
associated with thin fibrous caps and large lipid core of coronary atherosclerosis. 
 Study by(Kohet al.,2008) found that MMP-9 (-1562C>T) polymorphism was significantly and independently 
Journal of Biology and Medical Sciences - JBMS 
An Open Access International Journal published by University of Babylon, Iraq 
Vol.1 2013 
 
24 
associated with acute myocardial infarction. Our study indicated heterozygote C>T was higher in STEMI 
subjects as compared to NSTEACS.( Morgan et al.,2003) showed in -1562C>T polymorphism, -1562T allele 
had a higher transcriptional activity as compared to that of -1562C allele. Similarly,( Kim et al., 2002) reported 
that the substitution of C>T at -1562 promoter will provide a higher promoter activity of the T-allelic promoter. 
This fact contributes to elevated MMP-9 in the plaque which is detected in serum during plaque rupture in 
subjects with MMP-9 (-1562C>T) polymorphism. The mechanism whereby the MMP-9 allele contributes to 
CAD and atherosclerosis is unknown. Atherosclerosis is apparently initiated in response to arterial endothelial 
injury, which allows increased permeability to lipid, monocytes and lipid-laden macrophages. The MMP-
9secreted from macrophages apparently helps medial smooth muscle to migrate into the intima by degrading 
extracellular matrix( Robertson et al .,2007).  
(Zhiet al .,2010)reported that −1562 CT/TT genotypes may contribute to CAD in diabetics and MI in CAD 
patients in a Chinese population. ( Fallahetal.,2010)found that the −1562 C>T polymorphism in the MMP- 9 
gene potentially plays a role in the manifestation of coronary atherosclerosis but does not affect the number of 
diseased vessels. The results of their study were not consistent. Three published studies on 788 Caucasians, 248 
Koreans and 2731 German men with angiographically documented CAD failed to confirm an association with 
the T allele( Kim et al.,2002; Haberbosch and Gardemann,2005). 
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